Logo image of AQB

AQUABOUNTY TECHNOLOGIES (AQB) Stock Fundamental Analysis

NASDAQ:AQB - Nasdaq - US03842K3095 - Common Stock - Currency: USD

0.6778  +0.02 (+2.7%)

After market: 0.6528 -0.02 (-3.69%)

Fundamental Rating

2

Overall AQB gets a fundamental rating of 2 out of 10. We evaluated AQB against 572 industry peers in the Biotechnology industry. Both the profitability and financial health of AQB have multiple concerns. AQB is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year AQB has reported negative net income.
In the past year AQB has reported a negative cash flow from operations.
In the past 5 years AQB always reported negative net income.
In the past 5 years AQB always reported negative operating cash flow.
AQB Yearly Net Income VS EBIT VS OCF VS FCFAQB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -62.40%, AQB is doing worse than 60.56% of the companies in the same industry.
AQB has a Return On Equity (-73.45%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -62.4%
ROE -73.45%
ROIC N/A
ROA(3y)-11.61%
ROA(5y)-18.33%
ROE(3y)-12.9%
ROE(5y)-21.71%
ROIC(3y)N/A
ROIC(5y)N/A
AQB Yearly ROA, ROE, ROICAQB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2K 4K 6K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AQB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AQB Yearly Profit, Operating, Gross MarginsAQB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K -15K

More info and screens

3

2. Health

2.1 Basic Checks

AQB does not have a ROIC to compare to the WACC, probably because it is not profitable.
AQB has less shares outstanding than it did 1 year ago.
AQB has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, AQB has a worse debt to assets ratio.
AQB Yearly Shares OutstandingAQB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
AQB Yearly Total Debt VS Total AssetsAQB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -3.67, we must say that AQB is in the distress zone and has some risk of bankruptcy.
AQB has a Altman-Z score of -3.67. This is comparable to the rest of the industry: AQB outperforms 45.03% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that AQB is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.05, AQB is not doing good in the industry: 62.83% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -3.67
ROIC/WACCN/A
WACC5.75%
AQB Yearly LT Debt VS Equity VS FCFAQB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

A Current Ratio of 3.02 indicates that AQB has no problem at all paying its short term obligations.
AQB's Current ratio of 3.02 is on the low side compared to the rest of the industry. AQB is outperformed by 64.57% of its industry peers.
AQB has a Quick Ratio of 2.98. This indicates that AQB is financially healthy and has no problem in meeting its short term obligations.
AQB has a Quick ratio of 2.98. This is in the lower half of the industry: AQB underperforms 62.65% of its industry peers.
Industry RankSector Rank
Current Ratio 3.02
Quick Ratio 2.98
AQB Yearly Current Assets VS Current LiabilitesAQB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

AQB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -10.88%.
AQB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -46.96%.
The Revenue has been growing by 98.62% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-10.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45%
Revenue 1Y (TTM)-46.96%
Revenue growth 3Y166.94%
Revenue growth 5Y98.62%
Sales Q2Q%-93.59%

3.2 Future

Based on estimates for the next years, AQB will show a small growth in Earnings Per Share. The EPS will grow by 0.45% on average per year.
Based on estimates for the next years, AQB will show a very strong growth in Revenue. The Revenue will grow by 25.81% on average per year.
EPS Next Y-136.44%
EPS Next 2Y29.94%
EPS Next 3Y0.17%
EPS Next 5Y0.45%
Revenue Next Year-65.64%
Revenue Next 2Y-29.74%
Revenue Next 3Y-42.53%
Revenue Next 5Y25.81%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
AQB Yearly Revenue VS EstimatesAQB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2M 4M 6M 8M
AQB Yearly EPS VS EstimatesAQB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AQB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AQB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AQB Price Earnings VS Forward Price EarningsAQB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AQB Per share dataAQB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.94%
EPS Next 3Y0.17%

More info and screens

0

5. Dividend

5.1 Amount

AQB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AQUABOUNTY TECHNOLOGIES

NASDAQ:AQB (3/7/2025, 8:05:20 PM)

After market: 0.6528 -0.02 (-3.69%)

0.6778

+0.02 (+2.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2024-11-05/bmo
Earnings (Next)03-31 2025-03-31/amc
Inst Owners12.78%
Inst Owner Change49.66%
Ins Owners1.86%
Ins Owner Change0%
Market Cap2.62M
Analysts45
Price Target1.02 (50.49%)
Short Float %3.98%
Short Ratio0.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16.81%
Min EPS beat(2)-35.17%
Max EPS beat(2)1.55%
EPS beat(4)1
Avg EPS beat(4)-40.96%
Min EPS beat(4)-88.49%
Max EPS beat(4)1.55%
EPS beat(8)3
Avg EPS beat(8)-19.84%
EPS beat(12)6
Avg EPS beat(12)-11.8%
EPS beat(16)7
Avg EPS beat(16)-15.74%
Revenue beat(2)1
Avg Revenue beat(2)20.22%
Min Revenue beat(2)-37.95%
Max Revenue beat(2)78.4%
Revenue beat(4)1
Avg Revenue beat(4)2.44%
Min Revenue beat(4)-37.95%
Max Revenue beat(4)78.4%
Revenue beat(8)3
Avg Revenue beat(8)-1.66%
Revenue beat(12)4
Avg Revenue beat(12)-5.84%
Revenue beat(16)4
Avg Revenue beat(16)-18.01%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.81%
EPS NY rev (1m)0%
EPS NY rev (3m)-56.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)33.33%
Revenue NY rev (1m)0%
Revenue NY rev (3m)9.56%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.08
P/FCF N/A
P/OCF N/A
P/B 0.03
P/tB 0.03
EV/EBITDA N/A
EPS(TTM)-7.54
EYN/A
EPS(NY)-2.3
Fwd EYN/A
FCF(TTM)-6.16
FCFYN/A
OCF(TTM)-4.77
OCFYN/A
SpS0.33
BVpS25.86
TBVpS25.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -62.4%
ROE -73.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-11.61%
ROA(5y)-18.33%
ROE(3y)-12.9%
ROE(5y)-21.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 376.96%
Cap/Sales 425.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.02
Quick Ratio 2.98
Altman-Z -3.67
F-Score2
WACC5.75%
ROIC/WACCN/A
Cap/Depr(3y)2283.86%
Cap/Depr(5y)1466.75%
Cap/Sales(3y)1807.69%
Cap/Sales(5y)2010.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45%
EPS Next Y-136.44%
EPS Next 2Y29.94%
EPS Next 3Y0.17%
EPS Next 5Y0.45%
Revenue 1Y (TTM)-46.96%
Revenue growth 3Y166.94%
Revenue growth 5Y98.62%
Sales Q2Q%-93.59%
Revenue Next Year-65.64%
Revenue Next 2Y-29.74%
Revenue Next 3Y-42.53%
Revenue Next 5Y25.81%
EBIT growth 1Y10.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-154.54%
EBIT Next 3Y30.8%
EBIT Next 5Y19.8%
FCF growth 1Y65.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.75%
OCF growth 3YN/A
OCF growth 5YN/A